Desvenlafaxine Tablet, Film Coated, Extended Release
Product Images NDC 71335-1700

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 71335-1700). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1.jpg (Figure1)

A forest plot chart displaying the pharmacokinetic geometric mean ratios (90% confidence intervals) of Desvenlafaxine for Cmax and AUC by renal and hepatic impairment severity, and by population description (gender and age groups). The x-axis shows change relative to reference, ranging from 0.50 to 3.5. The chart illustrates how Desvenlafaxine exposure varies with mild, moderate, severe renal and hepatic impairment, and also by females, ages 65-75, and over 75 years.*

FDA Label Image

Figure2.jpg (Figure2)

A forest plot depicting the pharmacokinetic changes of desvenlafaxine when coadministered with ketoconazole, a CYP3A4 inhibitor. The plot shows geometric mean ratios with 90% confidence intervals for Cmax and AUC, indicating changes relative to a reference value on a horizontal axis ranging from 0.50 to 2.0.*

FDA Label Image

Figure3.jpg (Figure3)

A forest plot chart showing geometric mean ratios (90% confidence intervals) for pharmacokinetic changes in Cmax and AUC of interacting drugs when administered with Desvenlafaxine (Pristiq) at various dosages (50 mg, 100 mg, 400 mg). Drugs include Desipramine, Midazolam, Tamoxifen, and Aripiprazole with respective metabolite results indicated. The x-axis indicates change relative to reference (0.5 to 2.5).*

FDA Label Image

Figure4.jpg (Figure4)

A Kaplan-Meier curve illustrating the estimated proportion of patients with relapse over time (days from randomization) comparing Desvenlafaxine 50 mg and placebo. The y-axis shows relapse percentage up to 50%, and the x-axis spans up to 200 days. The solid line represents Desvenlafaxine, while the dashed line represents placebo.*

FDA Label Image

Figure5.jpg (Figure5)

A line graph showing the estimated proportion of patients with relapse over time in days from randomization. The x-axis represents time in days up to 200, and the y-axis represents the estimated proportion of patients with relapse from 0 to 50. Two lines plot the data: a solid line for Desvenlafaxine and a dashed line for placebo, indicating relapse rates over time for each group.*

FDA Label Image

Image 04

Chemical structure diagram showing the molecular formula of Desvenlafaxine, the active ingredient in the Desvenlafaxine 50 mg extended-release oral tablet by Bryant Ranch Prepack.*

FDA Label Image

Label Image (Lbl713351700)

Desvenlafaxine ER 50 mg Tablet packaging label by Bryant Ranch Prepack. The label compares the product to Pristiq 50 mg Tablet from West-Ward Columbus Inc. It indicates packaging quantity of 30 tablets and includes storage instructions to keep at room temperature 20°-25°C (68°-77°F). The label carries the NDC 71335-1700-1 and a barcode, with additional lot and RX only information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.